Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study. Yuan, Z., DeFalco, F., Wang, L., Hester, L., Weaver, J., Swerdel, J. N., Freedman, A., Ryan, P., Schuemie, M., Qiu, R., Yee, J., Meininger, G., Berlin, J. A., & Rosenthal, N. Curr Med Res Opin, 36(7):1117-1124, 2020.
doi  bibtex   
@article{RN212,
   author = {Yuan, Z. and DeFalco, F. and Wang, L. and Hester, L. and Weaver, J. and Swerdel, J. N. and Freedman, A. and Ryan, P. and Schuemie, M. and Qiu, R. and Yee, J. and Meininger, G. and Berlin, J. A. and Rosenthal, N.},
   title = {Acute pancreatitis risk in type 2 diabetes patients treated with canagliflozin versus other antihyperglycemic agents: an observational claims database study},
   journal = {Curr Med Res Opin},
   volume = {36},
   number = {7},
   pages = {1117-1124},
   ISSN = {0300-7995},
   DOI = {10.1080/03007995.2020.1761312},
   year = {2020},
   type = {Journal Article}
}

Downloads: 0